Nanotechnology in Medicine - Nanomedicine http:
Post# of 63839
Posted On: 11/23/2016 3:57:21 PM
Nanotechnology in Medicine - Nanomedicine
http://www.understandingnano.com/medicine.html
PMCB - Pharmacyte Biotech Inc. - http://pharmacyte.com/
The Cell-in-a-Box® live cell encapsulation technology employed by PharmaCyte Biotech is a “platform” upon which treatments for different diseases may be built. This technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them. The focus of PharmaCyte Biotech using this technology is to develop treatments for various forms of cancer, particularly pancreatic cancer, for abdominal cancers, for breast cancer and for diabetes
PharmaCyte Biotech has acquired the worldwide exclusive rights to this live cell-encapsulation technology for the development of treatments for all types of cancer and for diabetes. The rights to use the cancer prodrug-activating cells that will be part of our treatments for advanced pancreatic cancer and breast cancer were also acquired.
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova, has officially opened its new facilities at Synapse within Biopolis in Singapore. Biopolis is a world-class biomedical sciences hub where key research organizations and institutes are located from around the globe
http://www.otcmarkets.com/stock/PMCB/news?id=96082
http://www.understandingnano.com/medicine.html
PMCB - Pharmacyte Biotech Inc. - http://pharmacyte.com/
The Cell-in-a-Box® live cell encapsulation technology employed by PharmaCyte Biotech is a “platform” upon which treatments for different diseases may be built. This technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them. The focus of PharmaCyte Biotech using this technology is to develop treatments for various forms of cancer, particularly pancreatic cancer, for abdominal cancers, for breast cancer and for diabetes
PharmaCyte Biotech has acquired the worldwide exclusive rights to this live cell-encapsulation technology for the development of treatments for all types of cancer and for diabetes. The rights to use the cancer prodrug-activating cells that will be part of our treatments for advanced pancreatic cancer and breast cancer were also acquired.
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova, has officially opened its new facilities at Synapse within Biopolis in Singapore. Biopolis is a world-class biomedical sciences hub where key research organizations and institutes are located from around the globe http://www.otcmarkets.com/stock/PMCB/news?id=96082
(0)
(0)